share_log

Stephens & Co. Reiterates Overweight on Cytek Biosciences, Maintains $6 Price Target

Benzinga ·  Mar 19 14:07

Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 239

Recommended

Write a comment